Eugenia M. Ramos-Davila

Eugenia M. Ramos-Davila

Auto-generated profile, based on publicly available information

Eugenia M. Ramos-Davila

Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2024 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
MQManuel E. Quiroga-Garza
Manuel E. Quiroga-Garza
EREugenia M. Ramos-Dávila
Eugenia M. Ramos-Dávila
JPJezreel Pantaleón-García
Jezreel Pantaleón-García
AKAli Khodor
Ali Khodor
VPVictor L. Perez
Victor L. Perez

13 April 2022 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
EREugenia M Ramos-Davila
Eugenia M Ramos-Davila
LGLucas A Garza-Garza
Lucas A Garza-Garza
KGKathia Gutierrez-Juarez
Kathia Gutierrez-Juarez
JHJulio C Hernandez-Camarena
Julio C Hernandez-Camarena
ARAlejandro Rodriguez-Garcia
Alejandro Rodriguez-Garcia
Background/aims To evaluate the role of early immunosuppressive therapy (IMT) in the management of rheumatoid arthritis (RA)-associated peripheral ulcerative keratitis (PUK). Methods Single-centre, retrospective, comparative cohort study. Patients with RA-associated PUK were divided into two groups; those exposed to and those not exposed to early IMT, defined as administrating therapy within the first 4 weeks from the PUK onset. Outcomes included PUK recurrence, control of inflammation and development of ocular complications, including corneal scarring and perforation, cataract formation or progression and permanent visual loss. Results A total of 52 eyes from 36 patients were included for analysis; 37 (71.2%) eyes received early IMT and 15 (28.8%) eyes did not. Follow-up time was 41.2+53.3 months (range: 4–236 months). While early IMT was a protective factor (HR 0.345, 95% CI 0.126 to 0.946, p=0.039), late RA diagnosis after PUK onset (HR 4.93, 95% CI 1.75 to 13.85, p=0.002) and retarded (≥2 months) control of inflammation (HR 8.37, 95% CI 1.88 to 37.16, p=0.005) were risk factors for PUK recurrence. Late IMT (OR 7.75, 95% CI 2.00 to 29.99, p=0.003), an unknown diagnosis of RA at first visit (OR 4.14, 95% CI 1.15 to 14.91, p=0.030) and at least one PUK recurrence (OR 6.42, 95% CI 1.71 to 24.07, p=0.006) were risk factors for visual loss. Survival analysis rendered eyes exposed to early IMT a lower risk of PUK recurrence (p=0.039). Conclusion Eyes with RA-associated PUK exposed to early IMT were more likely to achieve earlier inflammatory control, fewer recurrences and had better visual outcomes.

6 March 2024 in Ophthalmology
Verified
Journal Article
Closed access
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
MCMaria F. Colorado-Zavala
Maria F. Colorado-Zavala
EREugenia M. Ramos-Dávila
Eugenia M. Ramos-Dávila
MQManuel E. Quiroga-Garza
Manuel E. Quiroga-Garza
NANadim S. Azar
Nadim S. Azar
VPVictor L Perez
Victor L Perez

25 January 2022 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
JJJosé Carlos Jaime-Pérez
José Carlos Jaime-Pérez
EREugenia M. Ramos-Dávila
Eugenia M. Ramos-Dávila
EPErnesto Picón-Galindo
Ernesto Picón-Galindo
RJRaúl A. Jiménez-Castillo
Raúl A. Jiménez-Castillo
ALAndrés Gómez-De León
Andrés Gómez-De León
DGDavid Gómez-Almaguer
David Gómez-Almaguer
Acute myeloid leukemia (AML) is most commonly presented in older adults; however, it appears 10 years earlier in Latin American countries. Clinical evolution in older adults from this populations has not been characterized. We analyzed outcomes and survival predictors. Patients ≥ 55 years old diagnosed with AML at a hematology referral center from 2005 to 2020 receiving intensive chemotherapy (IC), low-dose cytarabine (LDAC) and best supportive care (BSC) were included. Survival analysis included the Kaplan-Meier and Cox models and the cumulative incidence of relapse (CIR). Seventy-five adults were included and the overall survival (OS) was 4.87, 1.67 and 1.16 months, using IC, LDAC and BSC, respectively. The IC led to a higher OS (p < 0.001) and was a protective factor for early death, at a cost of more days spent hospitalized and more non-fatal treatment complications; non-significant differences were found between the LDAC and BSC. Eight (10.7%) patients underwent hematopoietic cell transplantation, with a higher OS (p = 0.013). Twenty (26.7%) patients achieved complete remission; 12 (60%) relapsed with a 6-month CIR of 57.9% in those < 70 years old vs. 86.5% in those ≥ 70 years old, p = 0.034. Multivariate analysis showed the white blood cell count (WBC) and IC had a significant impact on the patient survival, whereas chronological age and the Charlson comorbidity index (CCI) did not. AML in low-middle income countries demands a different approach; the IC improves survival, even with a high incidence of relapse, and should be offered as first-line treatment. Eligibility criteria should include WBC and a multidimensional evaluation. The age per se and the CCI should not be exclusion criteria to consider IC.

29 September 2021 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
JJJosé Carlos Jaime-Pérez
José Carlos Jaime-Pérez
MGMariana González-Treviño
Mariana González-Treviño
JMJesús D. Meléndez-Flores
Jesús D. Meléndez-Flores
EREugenia M. Ramos-Dávila
Eugenia M. Ramos-Dávila
OCOlga G. Cantú-Rodriguez
Olga G. Cantú-Rodriguez
DGDavid Gómez-Almaguer
David Gómez-Almaguer

24 September 2024 in Ophthalmology Retina
Verified
Journal Article
Closed access
EREugenia M. Ramos-Dávila
Eugenia M. Ramos-Dávila
LDLauren A. Dalvin
Lauren A. Dalvin